Microvesicles:the functional mediators in sorafenib resistance  

作　　者：Cong He Doulathunnisa Jaffar Ali Bo Sun Bei-Cheng Sun Zhong-Dang Xiao 

机构地区：[1]State Key Laboratory of Bioelectronics,School of Biological Science and Medical Engineering,Southeast University,Nanjing 210096,Jiangsu,China [2]Department of Hepatobiliary Surgery,The Affiliated Drum Tower Hospital of Nanjing University Medical School,Nanjing 210008,Jiangsu,China

出　　处：《Cancer Drug Resistance》2022年第3期749-761,共13页癌症耐药（英文）

基　　金：supported by the National Natural Science Foundation of China(No.81671807);the Key Research&Development Program of Jiangsu Province(BE2020777);Fundamental Research Funds for the Central Universities(2242018K3DN05)to Z.D.X.;Fundamental Research Funds for the Central Universities(2242021K10004)to B.S.;the Jiangsu Postdoctoral Research Foundation(1601001C);Fundamental Research Funds for the Central Universities(2242016R20017)to J.A.D.

摘　　要：Overcoming drug resistance in cancer therapies remains challenging,and the tumor microenvironment plays an important part in it.Microvesicles(MVs)are functional natural carriers of cellular information,participate in intercellular communication,and dynamically regulate the tumor microenvironment.They contribute to drug resistance by transferring functional molecules between cells.Conversely,due to their specific cell or tissue targeting ability,MVs are considered as carriers for therapeutic molecules to reverse drug resistance.Thus,in this mini-review,we aim to highlight the crucial role of MVs in cell-to-cell communication and therefore their diverse impact mainly on liver cancer progression and treatment.In addition,we summarize the possible mechanisms for sorafenib resistance(one of the main hurdles in hepatocellular carcinoma treatments)and recent advances in using MVs to reverse sorafenib resistance in liver cancer therapies.Identifying the functional role of MVs in cancer therapy might provide a new aspect for developing precise novel therapeutics in the future.

关 键 词：Microvesicles(MVs) sorafenib resistance tumor microenvironment cancer therapy 

分 类 号：R73[医药卫生—肿瘤]